Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection

New England Journal of Medicine

Volumn 346, Issue 26, 2002, Pages 2039-2046

  Walmsley, Sharon ^a,h   Bernstein, Barry ^b   King, Martin ^b   Arribas, José ^c   Beall, Gildon ^d   Ruane, Peter ^e   Johnson, Margaret ^f   Johnson, David ^e   Lalonde, Richard ^g   Japour, Anthony ^b   Brun, Scott ^b   Sun, Eugene ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ABBOTT LABORATORIES   (United States)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e Tower Infectious Diseases ^*

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g MCGILL UNIVERSITY   (Canada)

^h TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PLACEBO; STAVUDINE; VIRUS RNA;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NELFINAVIR; PROPORTIONAL HAZARDS MODELS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; STAVUDINE; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 0037182766     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012354     Document Type: Article

References (34)

1. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993
2. Decline in deaths from AIDS due to new antiretrovirals
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Deaths: Final data for 1998
5. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
6. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
7. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study: Swiss HIV Cohort Study
8. Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
9. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
10. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
11. Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100 mg BID) in HIV-infected subjects when taken with food
12. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results
13. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine
14. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA panel
15. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
16. HIV-protease inhibitors
17. Indinavir concentrations and antiviral effect
18. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir
19. Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy
20. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
21. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
22. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study
23. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
24. Pharmacokinetic interactions between two human immunodeficiency virus inhibitors, ritonavir and saquinavir
25. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
26. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
27. The Atlantic Study: A randomized open-label study to evaluate the efficacy and safety of three triple-combination therapies aimed at different HIV targets in antiretroviral naïve HIV-1 infected patients
28. A randomized open multicenter trial comparing nelfinavir or nevirapine in HIV-infected naïve patients (the Combine Study)
29. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV infected adults: A randomized equivalence trial
30. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
31. Nelfinavir: An update on its use in HIV infection
32. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)
33. Genetic correlates of virologic response to an indinavir-containing salvage regimen in patients with nelfinavir failure